Celadon Pharmaceuticals Plc (LSE:CEL) has announced a temporary suspension of trading on AIM after postponing the release of its Annual Report and Accounts. The delay has prompted the company to pause trading activity while it works to resolve outstanding reporting requirements.
Despite this setback, Celadon has secured an additional £1 million in debt financing and is actively negotiating a potential £20 million investment. The latter deal is conditional upon the company transitioning from a public to a private entity, signaling a possible shift in strategic direction.
Operationally, the company is managing regulatory hurdles that have delayed the execution of a European contract. Meanwhile, a new product launch in the UK is on the horizon, reflecting continued momentum in its domestic market. Celadon has also expanded its cultivation infrastructure and successfully delivered its first shipment to a U.S.-based customer—an early step into the promising American medical cannabis market.
Company Profile: Celadon Pharmaceuticals Plc
Celadon Pharmaceuticals is a UK-based firm focused on the research, manufacture, and sale of cannabis-derived medicines aimed at treating chronic pain and neurological conditions, including autism. Its operations are anchored by a 100,000-square-foot EU-GMP certified facility equipped for large-scale cultivation and extraction. The company also holds a Home Office license for commercial cannabis supply and is running a clinical trial targeting chronic pain. Additionally, Celadon maintains a minority stake in Kingdom Therapeutics, which is developing cannabinoid-based therapies for autism.
Leave a Reply